Sign in
Taking peopleNo phase

Curcumin in Critically Ill Patients With Sepsis

Key facts

Who runs it
Hospital Civil de Guadalajara
Where
Mexico1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
56 people, planned
Started
1 Mar 2026
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Curcumin
  • Placebo
Record updated
17 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Patients older than 18 years of either sex
  • Critically ill patients with a diagnosis of sepsis admitted to the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde."
  • Patients receiving enteral nutrition
  • Written informed consent signed by the patient or their legally authorized representative

Who cannot take part

  • Patients receiving exclusively parenteral nutrition
  • Patients with a history of allergy or hypersensitivity to curcumin
  • Patients with autoimmune diseases or severe immunosuppression
  • Patients in a terminal condition with a life expectancy of less than 48 hours
  • Patients with intolerance to enteral feeding, intestinal ischemia, intestinal obstruction, pancreatitis or short bowel syndrome
  • Patients with acute liver failure or decompensated liver cirrhosis
  • Patients with clinically significant active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage, etc.)
  • Patients requiring therapeutic anticoagulation (warfarin, direct oral anticoagulants [DOACs], or full-dose heparin)
  • Pregnant or breastfeeding women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

This trial is currently available in Mexico.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes overwhelming and damages its own organs. It is one of the leading causes of death in critically ill (very sick) patients worldwide. Despite advances in antibiotics, intensive care, and life-support technologies, sepsis remains difficult to treat because much of the harm comes not only from the infection itself, but from an exaggerated and uncontrolled inflammatory response in the body. When a person develops sepsis, the immune system releases large amounts of inflammatory substances meant to fight infection. However, in many cases this response becomes excessive, leading to organ failure, prolonged stays in the intensive care unit (ICU), and increased risk of death. Current treatments focus mainly on controlling the infection and supporting failing organs, but there are limited therapies that directly help regulate this harmful immune overreaction. Curcumin is a natural compound found in turmeric, a spice commonly used in food. In laboratory studies and some clinical research, curcumin has shown anti-inflammatory and antioxidant properties. It appears to influence several pathways in the immune system that are involved in the inflammatory process. However, its potential benefits in patients with severe infections such as sepsis have not been fully studied in a rigorous clinical setting. The purpose of this clinical trial is to evaluate whether curcumin, when added to standard medical treatment, can help modulate (regulate) the immune response in critically ill patients with sepsis. This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde" in Guadalajara, Mexico. "Randomized" means that participants will be assigned by chance to receive either curcumin or a placebo (a look-alike substance that contains no drug). "Double-blind" means that neither the patients nor the healthcare team will know who is receiving curcumin and who is receiving the placebo during the study. This design helps ensure that the results are objective and scientifically reliable. Participants in the study will continue to receive all standard treatments for sepsis, including antibiotics and intensive care support. The study will measure inflammatory markers in the blood, organ function, and important clinical outcomes such as the need for organ support and length of stay in the ICU. Safety will also be carefully monitored.

Read full original descriptionShow less

Hypothesis:

The investigators hypothesize that in critically ill patients with sepsis, the addition of curcumin to standard treatment will help regulate the excessive inflammatory response, leading to improved biological markers of inflammation and potentially better clinical outcomes, compared to standard treatment alone. If curcumin proves to be beneficial and safe in this population, it could represent an accessible and relatively low-cost complementary therapy to improve the management of sepsis. However, this study is necessary to determine scientifically whether these potential benefits are real and clinically meaningful. The ultimate goal of this research is to contribute new evidence that may improve the care and survival of patients suffering from one of the most severe and challenging conditions treated in intensive care medicine.

The 2 groups in the trial

  • Curcumin + Standard of CareTreatment being tested

    Participants in this arm will receive standard-of-care treatment for sepsis plus adjunctive curcumin administered enterally. Each patient will receive 2 capsules of curcumin (enhanced-bioavailability curcumin formulation containing 20% curcumin), 500 mg per capsule (100 mg of curcumin per capsule), three times daily for 10 days. This corresponds to a total of 6 capsules per day, providing 600 mg of curcumin daily. Treatment will begin within the predefined enrollment window after diagnosis. All other treatment, including antimicrobials and organ support, will remain at the discretion of the treating team.

    Treatment: Curcumin

  • Placebo + Standard of CarePlacebo, for comparison

    Participants in this arm will receive standard-of-care treatment for sepsis plus a matched placebo administered enterally. Patients will take 2 starch-based capsules three times daily for 10 days (total of 6 capsules per day), following the same schedule as the experimental arm. The placebo capsules are identical in appearance and packaging to the active product to maintain blinding. All other tratment, including antimicrobials and organ support, will remain at the discretion of the treating team.

    Treatment: Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunomodulatory Effect of Curcumin in Critically Ill Patients With Sepsis at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde": A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Criteria questions
Built from NCT07436130, who can take part
Record updated
17 September 2026